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Abstract
Phenotypic and genetic/allelic heterogeneity is a feature of many neuromuscular disorders, titinopathies being one of them. Hereditary
Myopathy with Early Respiratory Failure (HMERF) has been considered an extremely rare disease with definite clinicopathologic hallmarks, and
geographically restricted to the Northern European population with one single titin gene defect identified in previous years. The recent availability
of massive parallel sequencing techniques, allowing the screening of all coding regions of the genome in undiagnosed patients, together with a
growing awareness of the main muscle MRI features of the disease, has led to the discovery of a number of HMERF families and new titin
mutations in the last five years. We reviewed the clinical, pathological and muscle imaging findings that are still cornerstones for the diagnosis of
this disease, as well as the most recent molecular genetic findings. HMERF is more common and geographically widespread than previously
expected, and the knowledge of the whole phenotypic and molecular spectrum of HMERF can increase the number of diagnosed patients
considerably.
© 2017 Elsevier B.V. All rights reserved.
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1. Introduction
Since its original description more than 20 years ago, only
scattered sporadic cases or single families, mainly belonging to
Northern European populations, have been reported as affected
by Hereditary Myopathy with Early Respiratory Failure
(HMERF, OMIM#603689) before 2012. HMERF was therefore
thought to be an extremely rare disease. In the last five years,
several papers provided insights on new molecular genetic data
and detailed phenotype, pointing out that HMERF could indeed
be less exceptional, and that patients can be identified on the
basis of consistent muscle imaging findings, even without
typical clinical phenotype or muscle pathology.
The aim of this review is to summarize the known features
and the recent advances in the understanding of this more and
more recognized but still likely underdiagnosed disease.
2. Historical notes
Lars Edström and coworkers described HMERF for the first
time as a separate nosological entity in 1990 [1]. The authors
reported 16 patients from 7 Swedish families characterized by
the following clinical and laboratory features:
1) respiratory failure, often developing subacutely and
frequently being the symptom at onset of the disease;
2) limb-girdle distribution of muscle weakness
accompanied by foot extensor and neck flexor weakness;
3) myopathic findings on electromyography and normal or
slightly elevated serum creatine kinase level;
4) absence of neuropathy and heart involvement;
5) autosomal dominant mode of inheritance of the disease,
with onset between the second and the fifth decade.
On muscle biopsy, the hallmark of HMERF was the presence
of circumscribed “plaques” which were eosinophilic on
hematoxylin and eosin and stained red, purple or dark green on
Gomori trichrome [1]. These plaques were strongly reactive
with phalloidin suggesting they contained filamentous actin,
while desmin was largely absent from them. At the
* Corresponding author. Istituto di Neurologia, Università Cattolica del Sacro
Cuore, Fondazione Policlinico Universitario “A. Gemelli”, LargoA. Gemelli, 8,
00168, Rome, Italy.
E-mail address: giorgiotasca81@gmail.com (G. Tasca).
https://doi.org/10.1016/j.nmd.2017.12.002
0960-8966/© 2017 Elsevier B.V. All rights reserved.
Available online at www.sciencedirect.com
Neuromuscular Disorders 28 (2018) 268–276
www.elsevier.com/locate/nmd
ScienceDirect
ultrastructural level, these plaques were described as
“filamentous masses” with an electron density that was lower
than the Z-disks, and the other finding was myofibrillar lesions
with medium dense streaks of material arising from the Z-disk
over the sarcomere [1].
Some other reported patients were classified as cytoplasmic
body myopathy (CBM) with respiratory failure but no genetic
data have been published on these patients. These included a
family where the mother and two siblings had features
reminiscent of congenital myopathy such as long narrow face,
scoliosis and facial weakness [2]. The children presented at age
13 with respiratory failure, while the mother had mild proximal
weakness at age 55 and CBs on muscle biopsy. Other early
onset or congenital CBMs with respiratory failure were later
also considered to be affected by possible HMERF [3], as well
as fairly atypical sporadic patients such as one affected by
myopathy and axonal neuropathy, with weakness of neck
flexors since childhood, severe respiratory impairment which
was the cause of death at age 31 and CBs only in type 1 fibers
[4]. Importantly, a handful of families with autosomal dominant
inheritance from different ethnic backgrounds were also
retrospectively or prospectively identified, such as a Japanese
autosomal dominant CBM with respiratory involvement and
asymptomatic accumulation of CB-like structures in cardiac
and smooth muscles [5].
In the group of later genetically determined HMERF
titinopathies, two families need a special mention being the
most extensively investigated and best characterized from a
clinical and pathological point of view. In the family described
by Chapon et al. [6], affected individuals had onset between
18–40 years, often with respiratory failure, and normal creatine
kinase level. Pathology was rather homogeneous, with presence
of CBs, which stained for phalloidin and dystrophin, less
prominently using anti-actin antibodies. Desmin was present
only at their periphery, in the filamentous halo, and desmin
staining was increased in the cytoplasm of CB containing fibers
[7]. Chinnery et al. [8] reported one family with 11 affected
individuals over 2 generations with congophilic CBs and
rimmed-vacuolar myopathy (RVM), variable respiratory
dysfunction and predominant anterolateral lower leg muscle
involvement. Disease onset was slightly later (mean 50.2 years)
than previously described in HMERF. No other organ
involvement (including heart) was found on autopsy in one
patient [8].
On the whole, since the first description several names have
been used to define this condition, such as the eponym
“Edström myopathy” (OMIM database), or the clinically-
oriented “autosomal dominant myopathy with proximal
weakness and early respiratory muscle involvement” [9] and
“autosomal dominant distal myopathy with early respiratory
failure” [8], as well as the more general and pathology-oriented
“familial” [6] or “inherited cytoplasmic body myopathy [5].
3. Molecular genetic findings: a historical perspective
In two of the originally described Swedish families, a
genetic locus was established by linkage to the region 2q24-q31
[9]. The affected individuals from the two families shared a
common haplotype, which suggested an identical mutation with
the same origin. Titin was considered a strong candidate for the
disease, and one single change in titin, cosegregating with the
disease and associated with the identical haplotype was later
found in the two families linked by Nicolao et al. [9] and in one
sporadic patient [10]. This change was a C to T transition
resulting in an arginine to tryptophan substitution at codon 279
of the kinase domain (R279W, or p.R34091W, predicted
according to the longest theoretical titin transcript, NM
001267550), in exon 359, the first M-line exon (Mex1) of the
titin gene (TTN).
Titin is actually the biggest protein in the human cells and in
nature. TTN has 364 exons comprising the longest cDNA of
100 kb in the human genome: this makes it approximately 8
times bigger than DMD, the dystrophin gene. Titin is a
structural protein, which spans half of the sarcomere from
M-line to Z-disk, and thus can be descriptively divided into
portions that correspond to the four sarcomeric regions
identifiable on electron microscopy (EM): Z-disk, I-band,
A-band, and M-line. Titin has indeed diverse functions
segregated in different portions: mechanical functions,
contributing to passive tension and determining relaxed
sarcomere length, but also regulatory functions as many of the
structural proteins [11]. In particular, the serine-threonine
kinase domain, lying in the periphery of M-line titin close to the
A-band, is a mechanical sensor that regulates transcription and
other cellular functions through a complex network of direct
and indirect interactions with other proteins involved in
autophagy or protein degradation machineries (nbr1, p62,
MURF2), as well as transcription factors such as SRF. The
p.R34091W change appeared to perturb the interaction of titin
with nbr1 [10]. The localization of nbr1 was abnormal in the
patients’ muscles and p62 was accumulated in diseased fibers,
while MURF2 showed unusual nuclear signal. Given these
indications coming from molecular genetic and functional
studies, the p.R34091W change was considered to be disease-
causing in these patients.
After 2005, the identification of patients in whom the kinase
domain variant was excluded corroborated the idea that other
mutations could also be responsible for the disease [12].
However, despite continuous interest in TTN being a very
strong candidate as the causative gene also for non-kinase
domain mutated patients, the huge size of this gene made it
cumbersome to study until extensive genetic screening methods
became widely available.
In 2012, two groups identified, through whole exome
sequencing studies, the same causative missense mutation in
TTN exon 344, g.274375T>C - p.C31712R (previously named
as p.C30071R), in other HMERF families. The mutated residue
is located in the myosin-binding fibronectin-III (FN3) domain
119 of A-band titin (formerly A150 domain) [13]. One group
[14] identified this mutation in 8 affected individuals from three
apparently unrelated Swedish families, two of them reported in
the original Edström publication [1]. All the mutated patients
shared a common 6.99 Mb haplotype. Another group [15]
identified the same mutation in the family originally described
by Chinnery et al. and in two additional UK families, classified
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as affected by the same disease on the basis of clinical and
muscle imaging similarities. The UK families shared a
haplotype in chromosome 2 of 2.93 Mb. The clinical disease
spectrum was fairly broad, and included mild phenotype at
advanced age.
An international collaborative study [16] provided a
comprehensive evaluation on the clinical, morphological and
MRI findings of a large number of patients with very wide
geographic distribution, and also reported four novel mutations,
always in the same FN3 119 domain of titin A-band (exon 344),
one of them behaving in a peculiar semi-recessive/dominant
manner. This study also included the French family described
by Chapon et al. where a linkage study had excluded titin [17],
showing a novel g.274367C>G, p.P31709R mutation. Of note,
a later linkage study after reclassification of the patients based
on muscle imaging results allowed linkage to the titin locus and
the discovery of the TTNmutation. In HMERF, MRI thus seems
to be more sensitive than clinical and pathological data, which
provided both false positive and false negative results in the first
assessment of the members of this and other families. Other
novel dominant mutations were identified in one German and
one British family, besides the semi-recessive/dominant
g.274436C>T, p.P31732L mutation in Southern European
families [16,18]. The most common mutation in this cohort was
the p.C31712R, which was found in patients of Northern
European descent but also in one Italian and one Argentinian
family. Interestingly, the authors were able to identify some
sharing of alleles in the p.C31712R families with a haplotype of
1.3 Mb, suggesting a common founder with the p.C31712R
mutation. In another study, this mutation was found to be
relatively frequent in the UK and present in a proportion of
patients (5.5%) previously classified as molecularly
undiagnosed myofibrillar myopathies (MFMs) [19]. These
authors also identified the p.P31732L mutation in one UK
family with incomplete penetrance and a new p.N31786K
likely pathogenic variant in one Brazilian patient [19].
Other exome sequencing studies led to the discovery of novel
mutations causing HMERF: p.W31729L in the Japanese family
described byAbe et al. [20] and p.G31791D in a US family [21].
The latter group also extended the study of the A-band titin
region to a cohort of MFM patients from different ethnicities,
finding the p.C31712R mutation in two of them, one North
American with Indian ancestry and one Spanish. The Indian had
a different haplotype compared to the British shared one, thus
suggesting an independent origin of the two identical mutations
[22]. More recently, a Chinese patient with the p.C31712R
mutation not sharing the UK common haplotype has been also
reported [23]. Uruha et al. also described 17 additional HMERF
patients from Japan, confirming the highest prevalence of the
p.C31712R mutation, as well as reporting three novel missense
mutations (p.C31712Y, p.G31791R and p.G31791V) and one
non-frameshift deletion (g.284913_284921delGAGGGCAGT -
p. R31783_V31785del) in TTN exon 344 [24]. Clinical and
pathology data of the affected individuals in these latter studies
were very consistent with what was previously reported in this
disease. The location of TTN mutations so far associated with
HMERF is illustrated in Fig. 1.
The exact pathogenic role of the originally described kinase
variant is currently questioned. Evidences following its
publication suggested that this variant is present at very low
frequency in normal controls (dbSNP rs140319117) [16] and
therefore can be better classified as a polymorphism rather than
as a pathogenic mutation, and that the originally described
HMERF patients harboring the kinase variant also had the
semi-recessive mutation, p.P31732L [25,26], thus challenging
its role in causing HMERF. This prompted a debate [26–28]
between two different views: one supporting the hypothesis that
the kinase variant is totally harmless, and another one according
to which the kinase variant may interplay with the A-band
mutation on the same allele, which normally has an incomplete
penetrance [19], thus acting as a modifier of its effect (i.e.,
modulating either its penetrance or expressivity).
4. Clinical features and management
The typical features of the disease are the ones already
clearly reported in the original description [1]. The onset is in
adulthood and respiratory failure, which gives the name to the
disease, is consistently present although with different degrees
of severity. It is frequently evident in the early stages of the
disease and disproportionate to the degree of limb weakness. It
usually presents with exertional dyspnea and/or daytime
sleepiness and morning headache, which are symptoms of
nocturnal hypoventilation. Nocturnal monitoring of blood gases
(oximetry) is able to pick up the hypoventilation, and
pulmonary function tests in both standing and supine positions
can help to identify respiratory failure caused by muscle
weakness. Diaphragmatic weakness is usually present and can
be discovered as a significant drop (>25%) of forced vital
capacity in supine position. Hypercapnia and chronic
modifications of arterial blood gases may be evident as well. To
treat these patients, non-invasive mechanical ventilation is often
required, starting during the night hours.
Scapular winging due to both trapezius and serratus anterior
weakness may be present. Clinical presentation can be however
fairly variable, and even head drop with marked trapezius
hypotrophy and nasal speech or rigid spine have been reported
in some patients [12,23]. Some degree of asymmetry is well
compatible with the disease. Surprisingly for a mutation in
A-band titin, clinically relevant cardiomyopathy is not
common. Electromyography findings in rare cases showed
mixed neurogenic/myopathic patterns but peripheral
neuropathy is not present and not expected from mutant titin
[16]. A notable clinical hint often present is a striking
abdominal weakness in some cases leading to constipation
(Tasca and Udd, personal observations) (Fig. 2). Dysphagia has
also been sporadically reported [24]. Calf hypertrophy [14] or
sometimes hypotrophy [21] can be present as well (Fig. 2).
Initial clinical diagnosis may be suspicion of acid maltase
deficiency or facioscapulohumeral muscular dystrophy.
Management includes thorough and regular screening of
respiratory function and eventual support with non-invasive
ventilation, with the aim of both preventing acute respiratory
failure and improving patients’ quality of life. Cardiac function
workup is warranted in the light of recent findings suggesting
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that heart involvement may be associated at least with the
p.C31712R mutation [29]. Ankle-foot orthoses may be needed
in case of foot drop that impairs walking. There is no
standardized treatment for constipation, but patients may
benefit from diet adjustments with increased fiber intake,
behavioral advices and use of laxatives.
5. Muscle pathology
Patients with different mutations share common histological
findings. On routine stainings, the pathological signature of
HMERF is the presence of CBs, which are mostly present but
may be less striking at first glance or present in rare fibers only.
The location of CBs is generally subsarcolemmal, and they are
often multiple and gathered in circular formations surrounding
part or the whole fiber in transverse sections [24]. Some fibers
also show areas of myofibrillar disintegration, often in central
position, and another remarkable pathological feature is the
presence of rimmed vacuoles (RVs) (Fig. 3).
CBs may differ in size, but all of them display similar
immunohistochemical features. Myotilin and alpha-B crystallin
antibodies usually stain the whole body, as well as phalloidin
and anti-actin antibodies. Desmin is positive in a rim
surrounding the CBs (Fig. 3c). The areas of myofibrillar
disruption, which can be observed in fibers harboring CBs but
also in other fibers apparently devoid of them in transverse
sections, show affinity for myotilin, alpha-B crystallin, p62 and
desmin as reported in MFMs [30]. Remarkably, the CBs do not
stain with anti-titin I-band antibody, TDP43 or anti-ubiquitin
Fig. 1. Schematic representation of the titin protein with the 12 so far known mutations associated with HMERF. Reported mutations (see text for details):
p.C31712Y [24]; p. G31791D [21,24]; p.G31791V [24]; p.G31791R [24]; p.N31786K (likely pathogenic) [19]; p. R31783_V31785del [24]; P31732L [16,18,19,23];
p.W31729C [16]; p.W31729L [20]; p.W31729R [16]; p.C31712R [14–16,19,21,23,24]; p.P31709R [16]. The p.R34091W variant, not pathogenic by itself but
originally described as an HMERF causing mutation [10], is also represented (see text for details).
Fig. 2. Clinical features in HMERF disease. Abdominal weakness in two
HMERF patients (homozygous P31732L in a, heterozygous p.C31712R in b).
Calf hypotrophy (b) or hypertrophy (homozygous P31732L in c) are also
sometimes present.
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antibodies [16]. The autophagosome marker LC3 and p62/
sequestosome 1 label the RVs but are largely absent from the
bodies. TDP43 and p62 are sometimes present at the periphery
of the CBs [21] and may show a dotted signal in atrophic fibers,
as it happens in other RVMs, this being likely related to
autophagic activation pathways.
EM shows the typical appearance of CBs with a dense,
irregular core surrounded by a paler, filamentous halo (Fig. 3e).
It is also reported that CBs can be absent due to sampling bias.
Areas of completely dissolved myofibrils, or including just
remnants of intact myofilaments, are also present. Some
sarcomeres and myofibrils also show the peculiar semidense
accumulations in the shape of stripes connecting the Z-disks
and other Z-line abnormalities, such as Z-line streaming and
dispersion of the osmiophilic Z-disk material.
The above-mentioned alterations are not always widespread,
and frequently fascicles with groups of fibers containing the
CBs are intermingled with fascicles with only normal fibers
[14,19]. Thus, it is possible that the typical pathology could be
missed or overlooked in the routine diagnostic setting if the
biopsy is not properly targeted and the alterations are very
minor or even non-specific [15].
Fig. 3. Muscle pathology in HMERF disease (homozygous p.P30091L). Seriate hematoxylin and eosin (a) and modified Gomori Trichrome (b) showing the
presence of round, mainly subsarcolemmal cytoplasmic bodies in a cluster of fibers. Cytoplasmic bodies appear purple or dark green on Gomori staining. One fiber
harboring a rimmed vacuole (arrow) and another one with a central area of myofibrillar disruption that differs from cytoplasmic bodies (arrowhead) are also present.
Seriate desmin (c) and myotilin (d) stainings showing in two longitudinally oriented myofibers the intense reaction with myotilin of the cytoplasmic bodies that are
devoid of desmin except for a thin peripheral rim. An area of desmin positivity is also present in the center of the fiber. Electron micrograph (e) showing a typical
cytoplasmic body in longitudinal sectioning (e, scale bar: 5 microns). (f) Rimmed vacuolar pathology in a different patient.
272 G. Tasca, B. Udd /Neuromuscular Disorders 28 (2018) 268–276
6. Muscle imaging
The first report on muscle imaging of HMERF patients
documented an early involvement of the semitendinosus and
obturator externus with relative sparing of the biceps femoris
and semimembranosus in 7 affected members of the family
described by Chinnery et al [31]. The other most affected
muscles in the lower limbs were the iliopsoas, gracilis, anterior
leg muscles and, peculiarly, popliteus. Notably, in this first
study the authors already hypothesized the use of MRI for the
discovery of new families or sporadic cases with HMERF and
the testing of oligosymptomatic individuals, with implications
on respiratory follow-up. The pattern of involvement was later
confirmed and found to be very consistent in other HMERF
patients irrespective of the mutation [12,14–16,19–21,23,24].
Among the more than 50 patients imaged, including some
presymptomatic ones, only one did not display any involvement
of the semitendinosus [15]. Other helpful clues for the
diagnosis are the involvement of the gluteus minimus at pelvic
level, the sartorius at the thigh and the tibialis posterior at lower
leg level (Fig. 4) and a proximo-distal gradient of involvement
of the semitendinosus, which is evident until end-stage fatty
replacement. This pattern is highly suggestive because it
preferentially affects muscles that are normally spared in other
myopathies (such as the semitendinosus, sartorius, gracilis and
tibialis posterior). It could even be considered pathognomonic,
and the only caveat is the significant overlap with the pattern
reported in desminopathy and alpha-B crystallinopathy [32],
and exceptionally in LGMD2L [33].
While several studies have analyzed in detail the involvement
of lower limb muscles, just one reported on the scapular girdle
muscles and only in a few HMERF patients [31]. The most
affected muscles were the supraspinatus, infraspinatus and
serratus anterior with relative sparing of the pectoralis major and
subscapularis. In our patients we confirm, quite reliably, a severe
involvement of the serratus anterior to a lesser extent followed
by pectoralis minor, rhomboids, sternocleidomastoid and
subscapularis, a variable involvement of supra and infraspinatus
and the sparing of pectoralis major (Fig. 4) [12,34]
7. Open questions and conclusions
Mutations in TTN are known to cause different human
skeletal and cardiac muscle diseases. Titin is a major gene
responsible for dilated cardiomyopathies, mostly caused by
mutations that cluster in the A-band [35]. Skeletal muscle
diseases other than HMERF are caused by mutations in
C-terminal titin exons and include the autosomal dominant
tibial muscular dystrophy and the more severe recessive
LGMD2J, due to mutations in the two last exons 363 (Mex5)
and 364 (Mex 6), which are not associated with heart disease.
A severe recessive muscular dystrophy with lethal
cardiomyopathy also called Salih myopathy (due to mutations
found in Mex 1 and 3) [36], and more lately several other
myopathic phenotypes, such as recessive congenital myopathies
with prominent central nuclei [37], childhood-onset disorders
with or without contractures and cardiomyopathy [37], and
recessive distal myopathies [38] were also reported. The exact
mechanisms through which the different mutations in the titin
gene cause HMERF and the other diseases are still rather
obscure. Before the genetic defect was known, Edström
hypothesized a failure in the normal length determining
mechanism of actin polymerization, because of the presence of
filaments spanning between two Z-disks for lengths greater
than one sarcomere [1]. Interestingly, among the other
functions titin also acts as a molecular guide for sarcomere
assembly [39].
At variance with the elastic I-band titin, which performs as a
molecular spring, A-band is stiff and most of its residues are
highly conserved [40]. This high degree of conservation is
probably due to the need of keeping exact protein-protein
interactions in a dynamic environment where big, structural
proteins are very close to each other. One of such interactions
Fig. 4. Muscle imaging. Typical HMERF lower limb imaging in a patient with
p.C31712R mutation (a-d): peculiar involvement of the gluteus minimus and
medius (a, arrow) together with abdominal muscles (a, arrowhead) and
obturator externus (b, arrow) at the pelvic level, of the semitendinosus (c,
arrow), gracilis (c, arrowhead) and sartorius (c, asterisk) at the thigh level and
anterolateral compartment (d, arrow) and tibialis posterior (d, arrowhead) at the
leg level. Scapular girdle MRI scans (e-h) show prominent involvement of
serratus anterior (arrows) in patients with different mutations and different
degree of clinical severity (homozygous P31732L in e and g, heterozygous
p.C31712R in f, asymptomatic heterozygous P31732L in h).
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takes place between FN3 elements and sub-fragment 1 (S1) of
myosin [41], and perturbations of these interactions may
negatively influence spatial relationships between myosin heads
and actin filaments. However, A-band titin is still poorly
characterized from a structural and functional point of view and
it is highly likely that it holds many more specific and localized
important functions [13]. This could explain why the mutations
cluster in the same FN3 119 domain despite the pronounced
molecular similarities among all the FN3 domains.
Further insights on possible mechanisms come from
pathology studies. Although experimental evidences suggest an
increased tendency of FN3 domains to aggregate when the most
conserved proline are mutated to alanine [42], and an in vitro
decreased solubility of the FN3 119 domain harboring some
HMERF mutations has been shown [43], one surprising finding
is the absence of the mutated titin protein in the aggregates [16].
This is at variance from other diseases in which the mutations
increase the probability of the protein to form aggregates, and
in these cases the mutated protein is one of the main
components seeding the aggregates themselves, as it happens
for some FLNC mutations [44]. A possible hypothesis is that
HMERF mutations derange the normal dynamic interactions
with neighboring proteins, and eventually cause the alteration
of autophagy processes needed for maintenance and turnover
leading to secondary aggregation of other proteins and
autophagic RV pathology. Inappropriate triggering of
autophagy with a role in the process of fiber hypotrophy, as it
happens in other titinopathies and RVMs, had been also
postulated in the original paper by Edström, who found some
fibers with an increased lysosomal acid phosphatase activity
[1]. Ultrastructural pathology confirms that maintenance of
sarcomeric structures is altered in HMERF leading to
accumulations of proteins not correctly re-cycled in
combination with an impaired autophagic processing.
TTN is a highly polymorphic gene, and each whole exome,
whole genome or targeted sequencing study performed usually
brings back to the clinician several variants that could be
potential disease causing titin mutations. This challenge of
interpretation underlines the importance of deep phenotyping
in the next generation sequencing era, making it necessary to
correctly suspect HMERF on clinical and pathological grounds
to address the genetic testing. According to some of the most
recently published guidelines [45], population data (i.e.,
frequency in the databases such as the Genome Aggregation
Database, http://gnomad.broadinstitute.org), prediction of the
impact on the protein product, together with functional and
segregation data should be all considered to correctly interpret
the value of the discovered genomic variants in each gene. This
is particularly true for huge genes like TTN, for which the
creation of a locus specific genomic database that includes
associated phenotypic data has been encouraged [46]. In this
context, we must once more stress the value of muscle imaging
to correctly classify patients in segregation studies and deep
phenotype affected and clinically unaffected individuals in
families with suspect titinopathy.
The issue on the hypothesized pathogenic role of the kinase
variant is still opened. It is now clear that the kinase domain
change cannot cause HMERF by itself and should be
considered, at the current state of the art, as a polymorphism.
Studies are ongoing to clarify whether or not it might potentiate
the effect of the mutation in cis and thus manifest or worsen the
phenotype in a similar way to what has been already described
for other titinopathies [47]. Interestingly, the components of the
signaling complex interacting with the kinase domain (p62 and
nbr1) have been shown to have essential roles in regulating the
autophagy machinery in muscle [48,49].
Muscle imaging pattern is highly specific for HMERF, and
muscle MRI has been the tool used to pick up additional
families and clarify the known families for the genetic studies.
The main feature of the disease is the early and constant
involvement of the semitendinosus muscle. Other TTN
mutations preferentially hit muscles that are also affected in
HMERF, like the tibialis anterior [50]. Although the final
reasons for the extreme susceptibility to damage of the
semitendinosus, usually one of the most resistant in other
myopathies, as well as that for respiratory muscles are not
known, the level of titin expression or of its isoforms in
different muscles may contribute to this selectivity: a recent
study indeed showed an overexpression of transcripts of several
titin isoforms, and in particular those including distal A-band
exons, in the semitendinosus compared with other
posteromedial thigh muscles [51]. Interestingly, a similar
pattern of involvement is present in desminopathy and alpha-B
crystallinopathy. A possible, intriguing explanation at the
molecular level regards perturbed interactions between titin and
alpha-B crystallin [15], and since Z-disk structures are the first
to be altered in HMERF and desmin is involved in Z-disk
functions a connection at the molecular level is likely.
Involvement of the semitendinosus is a very sensitive imaging
marker, and subclinical semitendinosus involvement could be
even detected in presymptomatic patients [15,16]. This is of
importance because the identification of HMERF patients
before the onset of symptoms may allow the appropriate
screening for respiratory involvement, since respiratory failure
can be the presenting symptom in this disease.
The recent genetic data also provides significant new
understandings. Some of individuals harboring the so far most
common HMERF mutation (p.C31712R) share a core
haplotype, suggesting a common Northern European ancestry.
However, the discovery of a different haplotype in two families
suggests that this site is more likely to be a mutational hotspot,
with the possibility of de novo mutations occurring worldwide
[23]. Moreover, the existence of one mutation behaving in a
semi-recessive/dominant manner raises the possibility that the
frequency of heterozygous individuals with this mutation could
be higher than currently understood in the general population.
Carriers of this mutation show either a later onset milder
HMERF, or may be clinically healthy although showing signs of
myopathy on muscle imaging and thus having a subclinical
myopathy, or may not have any detectable sign of muscle
involvement even on MRI.
It would be useful to clarify whether the earlier onset or
congenital cases [2,3] and the severe CBM with onset in the
second decade, rapid progression and some atypical features like
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prominent ankle contractures [52] are caused bymutations in the
TTN gene, thus further expanding the spectrum of HMERF, or if
they are different diseases. Tentatively, similarly to one Italian
HMERF patient [12], the most severe cases could be due to two
TTNmutations. In particular, the disease reported by Patel et al.
[2] could fit with a semi-recessive/dominant inheritance with the
mother being a paucisymptomatic carrier. In other descriptions
the presence of additional complicating features such as axonal
neuropathy [4], could worsen the phenotype.
In terms of differential diagnosis, the main challenge regards
the distinction from other MFMs and in particular
desminopathies, due to the broad overlap on muscle imaging,
the possible overlap of clinicopathological features and the
autosomal dominant inheritance. The presence of CBs, the early
respiratory involvement and the absence of cardiomyopathy
should suggest a diagnosis of HMERF. CBs could represent the
initial lesion and their presence is still the most useful
pathological sign to address the genetic testing towards
HMERF rather than other MFMs. Thus, although overlaps with
MFM pathology [19] and proteomic profiles [53] are certainly
present, in our opinion it would be useful to pathologically
subclassify HMERF as a CBM in the context of MFMs. Other
possible clinical overlaps regard myopathies that could present
with or display a marked respiratory involvement in ambulant
patients such as congenital myopathies and in particular late-
onset nemaline myopathy, acid maltase deficiency,
inflammatory myopathies (anti Jo-1 myopathy), muscular
dystrophies due to lamin A/C gene mutations, and to a lesser
extent sarcoglycanopathies, LGMD2A and LGMD2I [54].
Myogenic causes of respiratory failure are not always easily
recognized and should also be distinguished from neurogenic
and myasthenic causes. When respiratory failure is not
clinically evident differential diagnosis with other adult onset
LGMDs or distal myopathies can be considered.
The advisable molecular diagnostic algorithm includes at the
moment at least the sequencing of TTN exon 344, followed by
whole TTN gene screening, in suspect cases. HMERF and
titinopathies in general are and will be increasingly recognized
now that novel techniques such as next-generation sequencing
allow the analysis of giant genes in a fast and cost-effective way.
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